Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Stanford University
Centre Oscar Lambret
TILT Biotherapeutics Ltd.
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
University Health Network, Toronto
Valo Therapeutics Oy
Herlev Hospital
Herlev Hospital
University of Pennsylvania
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
City of Hope Medical Center
Centre Hospitalier Universitaire Vaudois
University of Pennsylvania
National Institutes of Health Clinical Center (CC)
BioEclipse Therapeutics
M.D. Anderson Cancer Center
Fate Therapeutics
Fate Therapeutics
University of Pennsylvania
Fate Therapeutics
BGI, China
BGI, China
Karolinska University Hospital
Genocea Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
Mie University
Turnstone Biologics, Corp.
University Health Network, Toronto
Jonsson Comprehensive Cancer Center
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Louisiana State University Health Sciences Center Shreveport
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Mie University
Mayo Clinic